Treatment of advanced small cell lung cancer. Clinical case and literature review
Autor: | Konstantin V. Menshikov, Aleksandr V. Sultanbaev, Shamil I. Musin, Irina A. Menshikova, Ainur F. Nasretdinov, Nadezda I. Sultanbaeva |
---|---|
Rok vydání: | 2021 |
Předmět: |
atezolizumab
Oncology Cancer Research medicine.medical_specialty overall survival medicine.medical_treatment EP Regimen chemotherapy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Atezolizumab Internal medicine medicine Stage (cooking) Lung cancer RC254-282 Etoposide Chemotherapy business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Carboplatin respiratory tract diseases Regimen impower133 chemistry 030220 oncology & carcinogenesis small cell lung cancer immunotherapy business 030215 immunology medicine.drug |
Zdroj: | Современная онкология, Vol 23, Iss 1, Pp 112-115 (2021) |
ISSN: | 1815-1442 1815-1434 |
DOI: | 10.26442/18151434.2021.1.200726 |
Popis: | Lung cancer is one of the most common tumors in humans. The incidence is in one of the leading positions. In 2019 1327 patients with this pathology were identified in the Republic of Bashkortostan. Of these, with stage III of the disease 28.7%, with stage IV 45.8%, which is higher. Small cell lung cancer (SCLC) is one of the most prognostically unfavorable malignant tumors in humans. About 15% of lung tumors are SCLC. The first combination for the treatment of advanced SCLC after etoposide and platinum preparations was the combination of the etoposide + carboplatin (EP) regimen with atezolizumab. In the IMpower133 study, after a median follow-up of 13.9 months. median overall survival in the atezolizumab group was 12.3 months, and in the placebo group 10.3 months. In clinical observation, the effectiveness of the combination of the EP regimen with atezolizumab has been demonstrated. A patient with SCLC received 4 courses of EP therapy with atezolizumab and 14 injections of atezolizumab. The partial response achieved is retained. Case study efficacy and satisfactory safety profile of the combination of atezolizumab and the EP regimen. |
Databáze: | OpenAIRE |
Externí odkaz: |